November 7, 2008 - New R Series AED Code-Ready Defibrillators Unveiled

MEDIA CONTACTS:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com   

 

Kim Angelastro
Publicis Consultants | PR
+1 (212) 527-8866
kim.angelastro@publicic-pr.com

 

Two New R Series AED Code-Ready Defibrillators Unveiled at American Heart Association Scientific Sessions 08

New R Series Wireless Capability, Defibrillator Dashboard and 12-Lead Transmission Option Also Being Introduced by ZOLL

November 7, 2008CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it will debut two new models of its R Series® Code-Ready defibrillator for hospitals as well as preview other new resuscitation products in Booth #701 at the American Heart Association Scientific Sessions 2008 in New Orleans November 9-11th.

The new R Series BLS and R Series Plus are designed to extend simple, smart and ready defibrillation to every hospital department with advanced, cost-effective solutions for resuscitation. The R Series BLS is a simple, easy-to-use AED that becomes a full-featured, advanced life support device for critical care at the touch of a button. The R Series Plus, which also has both AED and ALS capabilities at the touch of a button, also has networking capabilities and See-Thru CPR®. Like all other ZOLL defibrillators, the models provide the Real CPR Help® feature. Both the BLS and Plus models are 510(k) pending.

The original R Series ALS, launched in November 2006, and these two new models, all use the same uniform operating system common to ZOLL defibrillators. The cables, paddles, batteries, handles and electrodes are also common to ensure clinicians won’t encounter a mismatch in a time of crisis. 

In addition, all R Series models incorporate wireless networking to ensure code-readiness.  Based on standard 802.11b WiFi technology, the R Series automatically sends an alert when its state of readiness is compromised. Early notification maximizes patient safety by letting the clinician intervene before the defibrillator is needed for a code. 

Also debuting at AHA is the Defibrillator Dashboard, an automated, online system for ensuring code-readiness. Since defibrillators are widely distributed throughout the hospital, and their use is both infrequent and extremely critical, this unique management tool helps clinical engineers manage a pool of defibrillators throughout a facility. This support capability offers tools for maximizing defibrillator readiness and reduces the total cost of ownership, including the most costly aspect—battery management.

A new wireless 12-lead transmission option for the E Series® defibrillator/monitor will also be previewed at AHA. This transmission option is easy-to-use, cost-effective and an integrated part of ZOLL’s end-to-end resuscitation data management and communications system. The E Series wireless option is pending 510(k) approval.

“ZOLL’s research and development efforts continue to focus on helping to improve survival rates from sudden cardiac arrest,” said Richard A. Packer, President and Chief Executive Officer of ZOLL.  “Since hospitals have embraced the Code-Ready R Series for its ability to simplify and speed up deployment of pacing and defibrillation therapy, we’re extremely pleased to be able to add the BLS for low acuity areas and the Plus for higher-acuity med-surg units. Each R Series model is fully upgradeable.”

Also on display at the ZOLL Booth:

  • The AutoPulse®Non-invasive Cardiac Support Pump is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse has been shown to improve survival to discharge in a major study published in the Journal of the American Medical Association (JAMA)*.

The AutoPulse offers a significant advantage over manual CPR because it moves more blood, more consistently, than is possible with human hands. AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion, while freeing clinicians in the catheterization lab to perform procedures with optimal vascular access and minimal visual compromises.

  • The LifeVest®Wearable Defibrillator, worn by patients at risk for SCA, continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device alerts the patient prior to delivering a shock.  The device releases a conductive gel onto the therapy electrodes to protect the skin, then delivers a shock to restore normal heart rhythm.  The entire event, from detecting a life-threatening arrhythmia to automatically delivering a defibrillation shock, usually occurs in less than a minute.  Timely defibrillation is the single most important factor in saving a SCA victim’s life.  This unique, non-invasive technology has a 98% first shock success rate for treating patients in SCA without requiring bystander intervention.
  • CodeNet ® is the first software system that allows hospital teams to better document, manage, and review cardiac arrest event and resuscitation information. CodeNet brings new improvements and efficiencies in data capture, event time synchronization, and case and aggregate reporting. It is the only system that time stamps logged events and synchronizes these times with defibrillator data, providing clinicians with a complete and accurate timeline of an entire cardiac arrest event.

Scientific Assembly Presentations

Eight scientific presentations related to ZOLL products and technology will be presented during the Scientific Assembly.  Some highlights of the presentations include:

  • A comparison of the success of the LifeVest wearable defibrillator with AED success in the home as reported in the Home AED Trial (HAT) demonstrates compliance would be 12 times better with the LifeVest.  Survival from an event would be 13 times better in comparison with reported HAT results.  The wearable defibrillator eliminates the bystander requirements and location constraints associated with AEDs, leading to significantly better detection of sudden cardiac arrest and delivery of defibrillation.
  • M.A. Peberdy, M.D., Virginia Commonwealth University, Richmond, in both oral and moderated poster presentations, will report the use of CPR feedback (ZOLL Real CPR Help® technology) improved the quality of chest compressions provided by healthcare professionals in a mannequin-testing scenario, and both depth and rate were improved with the feedback device.
  • Wanchun Tang, M.D., Weil Institute, Palm Springs, Calif., will present new research related to integrating mechanical chest compressions and defibrillation to reduce energy requirements, and improve the success of defibrillation and resuscitation by timing defibrillation shocks with specific phases of the mechanical compressions.   He will report significant benefit associated with such integration. 

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. 2008 marks the 25th anniversary of ZOLL’s resuscitation product development. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company,  and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995).  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2008.  You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2008 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, CodeNet, Code-Ready, R Series, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. One-Step is a trademark of ZOLL Medical Corporation. All product names are the property of their respective owners.

*Ong ME, Ornato JP et al. JAMA. 2006;295(22).